KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EPS (Basic) (2016 - 2025)

BeOne Medicines (ONC) has disclosed EPS (Basic) for 11 consecutive years, with $0.04 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 136.36% to $0.04 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.2, a 141.67% increase, with the full-year FY2025 number at $0.2, up 142.55% from a year prior.
  • EPS (Basic) was $0.04 for Q4 2025 at BeOne Medicines, down from $0.09 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.16 in Q3 2023 to a low of -$0.52 in Q4 2021.
  • A 5-year average of -$0.18 and a median of -$0.22 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): plummeted 650.0% in 2022, then surged 200.0% in 2025.
  • BeOne Medicines' EPS (Basic) stood at -$0.52 in 2021, then skyrocketed by 36.54% to -$0.33 in 2022, then rose by 18.18% to -$0.27 in 2023, then soared by 59.26% to -$0.11 in 2024, then skyrocketed by 136.36% to $0.04 in 2025.
  • Per Business Quant, the three most recent readings for ONC's EPS (Basic) are $0.04 (Q4 2025), $0.09 (Q3 2025), and $0.07 (Q2 2025).